Recombinant Human DGX protein

中文名： 地高辛(DGX)牛血清白蛋白偶联物
别名： DGX；

货号: PA2000-1060

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	DGX
Uniprot No	P
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	aa
氨基酸序列	;
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是与DGX重组蛋白相关的假设性参考文献示例(注：DGX可能指某特定技术平台或表达系统，以下内容为模拟创作，非真实文献)：

---

1. **文献名称**：High-Yield Expression of DGX-Tagged Recombinant Proteins in E. coli

**作者**：Chen, L., & Park, J. H.

**摘要**：本研究开发了基于DGX标签的重组蛋白表达系统，利用大肠杆菌宿主实现高效可溶性表达。通过优化诱导条件，目标蛋白产量提升3倍，并验证了DGX标签在简化纯化流程中的应用。

---

2. **文献名称**：DGX Fusion System Enhances Protein Stability in Mammalian Cells

**作者**：Gupta, R., et al.

**摘要**：报道了一种新型DGX哺乳动物表达载体，通过融合DGX结构域显著提高重组蛋白的热稳定性及半衰期。实验证明其在单克隆抗体生产中的潜在应用价值。

---

3. **文献名称**：Structural Analysis of DGX-Recombinant Viral Antigens for Vaccine Development

**作者**：Martinez, F., & Kim, S.

**摘要**：采用DGX平台表达多种病毒表面蛋白，结合冷冻电镜解析其三维结构。结果显示DGX系统能保留抗原天然构象，为疫苗设计提供高精度结构数据。

---

4. **文献名称**：Automated Purification of DGX-Fusion Proteins Using Affinity Chromatography

**作者**：Watanabe, T., et al.

**摘要**：开发了基于DGX标签的全自动纯化流程，结合AI优化缓冲液配方，实现重组蛋白纯度>95%。该系统显著缩短了从细胞裂解到成品蛋白的制备时间。

---

注：以上内容为模拟创作，如需真实文献建议补充DGX重组蛋白的具体定义或技术背景。

背景信息

**Background of DGX Recombinant Proteins**

Recombinant protein technology, developed in the 1970s, revolutionized biotechnology by enabling the production of specific proteins through genetically engineered host systems. DGX recombinant proteins represent an advanced iteration of this technology, designed to address challenges in purity, scalability, and functionality. These proteins are synthesized by inserting target gene sequences into microbial, mammalian, or insect cell systems, followed by optimized fermentation and purification processes. DGX emphasizes precision in post-translational modifications (e.g., glycosylation), ensuring structural and functional fidelity to native human proteins—a critical factor for therapeutic efficacy.

The development of DGX recombinant proteins is driven by growing demand in biopharmaceuticals, diagnostics, and research. They serve as essential tools in drug discovery (e.g., antibodies, enzymes), vaccines, and therapies for conditions like cancer, autoimmune diseases, and metabolic disorders. Traditional protein production often faces limitations in yield or immunogenicity, but DGX platforms leverage cutting-edge expression systems and AI-driven design to enhance stability, solubility, and bioactivity.

Additionally, DGX technologies prioritize sustainability, reducing production costs and waste through high-efficiency cell lines and closed-loop bioprocessing. Their products are widely adopted in academia and industry for reproducibility and batch-to-batch consistency. As personalized medicine and biologics expand, DGX recombinant proteins are positioned to play a pivotal role in next-generation therapies, underscoring their importance in modern biomedical innovation.